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Effects of Low Endothelial Shear Stress After Stent Implantation on
Subsequent Neointimal Hyperplasia and Clinical Outcomes in
Humans
Koki Shishido, MD; Antonios P. Antoniadis, MD, PhD; Saeko Takahashi, MD; Masaya Tsuda, MD; Shingo Mizuno, MD;
Ioannis Andreou, MD, PhD; Michail I. Papafaklis, MD, PhD; Ahmet U. Coskun, PhD; Caroline O’Brien, PhD; Charles L. Feldman, ScD;
Shigeru Saito, MD; Elazer R. Edelman, MD, PhD; Peter H. Stone, MD
Background-—In-stent hyperplasia (ISH) may develop in regions of low endothelial shear stress (ESS), but the relationship between
the magnitude of low ESS, the extent of ISH, and subsequent clinical events has not been investigated.
Methods and Results-—We assessed the association of poststent ESS with neointimal ISH and clinical outcomes in patients
treated with percutaneous coronary interventions (PCI). Three-dimensional coronary reconstruction was performed in 374 post-PCI
patients at baseline and 6 to 10 months follow-up as part of the PREDICTION Study. Each vessel was divided into 1.5-mm-long
segments, and we calculated the local ESS within each stented segment at baseline. At follow-up, we assessed ISH and the
occurrence of a clinically indicated repeat PCI for in-stent restenosis. In 246 total stents (54 overlapping), 100 (40.7%) were bare-
metal stents (BMS), 104 (42.3%) sirolimus-eluting stents, and 42 (17.1%) paclitaxel-eluting stents. In BMS, low ESS post-PCI at
baseline was independently associated with ISH (b=1.47 mm2 per 1-Pa decrease; 95% CI, 0.38–2.56; P<0.01). ISH was minimal in
drug-eluting stents. During follow-up, repeat PCI in BMS was performed in 21 stents (8.5%). There was no signiﬁcant association
between post-PCI ESS and in-stent restenosis requiring PCI.
Conclusions-—Low ESS after BMS implantation is associated with subsequent ISH. ISH is strongly inhibited by drug-eluting stents.
Post-PCI ESS is not associated with in-stent restenosis requiring repeat PCI. ESS is an important determinant of ISH in BMS, but
ISH of large magnitude to require PCI for in-stent restenosis is likely attributed to factors other than ESS within the stent. ( J Am
Heart Assoc. 2016;5:e002949 doi: 10.1161/JAHA.115.002949)
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P ercutaneous coronary intervention (PCI) with stentimplantation is a major therapeutic strategy in patients
with clinically evident coronary artery disease. However, in-
stent restenosis (ISR) is the main limitation of coronary
stenting, especially for bare-metal stents (BMS). The predom-
inant mechanism of ISR is neointimal in-stent hyperplasia
(ISH),1 resulting from proliferation and migration of vascular
smooth muscle cells (VSMCs). Drug-eluting stents (DES)
reduce neointimal ISH through inhibited VSMC growth and
delayed re-endothelialization and healing. The different mag-
nitude of ISH between BMS and DES has been demonstrated
in large-scale studies.2,3
Various factors inﬂuence ISH, such as arterial injury by
stent struts4 and endothelial dysfunction.5 In addition, local
hemodynamic factors, in particular, endothelial shear stress
(ESS), are important determinants of vascular biology and
atherosclerosis,6 eliciting multiple effects on endothelial cells
and VSMCs.7 Whereas early studies on the association
between ESS magnitude and ISH were controversial,8 most
recent investigations demonstrated an inverse relationship
between ESS and ISR after BMS implantation.9,10 In DES, only
a few similar studies were conducted, without reaching
deﬁnitive conclusions.11–13 Therefore, the effect of low ESS
within the stent on subsequent clinical events in humans
requires further investigation. Furthermore, stent overlap is
associated with increased ISR and lumen loss regardless of
stent type.14 Flow within the stents may be affected by
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overlapping segments, and the relationship between the
hemodynamics inside overlapping stents and in-stent out-
comes have not been examined in clinical settings.
This study aims to assess the association of immediate
post-PCI ESS with the anatomic natural history in stented
regions over a 6- to 10-month period and clinical outcomes
arising from ISR in a large patient cohort undergoing PCI for
an acute coronary syndrome (ACS). The analysis was based
on data from the Prediction of Progression of Coronary Artery
Disease and Clinical outcome Using Vascular Proﬁling of
Shear Stress and Wall Morphology (PREDICTION) Study with
focus on the investigation of stent outcomes.
Methods
Study Population
The PREDICTION study is a multicenter investigation at 17
clinical sites in Japan to identify the detailed coronary
hemodynamic and plaque characteristics at baseline (BL) that
would predict future cardiac events in 1-year follow-up (FU).
The primary PREDICTION analysis was reported previously.15
In brief, 506 Japanese patients with ACS who underwent PCI
of all culprit lesions were enrolled. Patients underwent
intracoronary vascular proﬁling (VP) with intravascular ultra-
sound (IVUS) and angiography of all major coronary arteries at
the time of PCI. A large subset of consecutive, unselected
patients underwent routine FU VP after 6 to 10 months to
assess the anatomic natural history in relation to antecedent
vascular characteristics. All patients had clinical FU at 1 year.
This report focuses on stent characteristics and stent
outcomes.
Three-Dimensional Reconstruction of Coronary
Arteries
The methods of intracoronary VP have been previously
described.16–19 In brief, IVUS and biplane coronary angiogra-
phy were utilized to create an accurate three-dimensional (3D)
representation of the coronary artery. IVUS was performed
with automated pullback at 0.5 mm/s. The lumen and outer
vessel wall were reconstructed from segmented end-diastolic
IVUS frames. Coronary blood ﬂow was calculated directly
from the time required for the volume of blood contained
within the portion of the artery under study to be displaced by
contrast material in coronary angiography.20 The stent was
considered only as a zone along the arterial wall and not as a
solid-body geometry. We did not investigate the contours or
geometry of individually modeled stents. The 3D geometry of
ISH was taken as the difference between the stented region
and the lumen area. ESS within the stented region at the
luminal surface of the artery was calculated as the product of
blood viscosity (calculated from the measured hematocrit)
and the gradient of blood velocity at the wall. The process of
data acquisition and analysis are highly reproducible.17 In the
computational ﬂuid dynamics (CFD) simulations, we impose
measured blood ﬂow to pass through the reconstructed
geometry under nonslip condition (zero velocity) on the
arterial walls. Mathematical model uses linear momentum
(the Navier-Stokes) equations to ﬁnd the velocity distribution
at the faces of computational cells. The CFD model also has
shear rates (velocity gradients) in every spatial direction to
solve the governing equations. Thus, the gradient of blood
velocity at the wall is determined from the shear rate at the
computational cell on the wall, as published before.17 More
speciﬁcally, magnitude of the shear rate is deﬁned based on
the strain rate tensor as follows:
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Here, i, j=1, 2, 3 are the 3 coordinate directions, and xi
and ui are, respectively, the dimension and velocity in the
direction i. _c above becomes velocity gradient in the normal
direction to the wall. In this study, we deﬁned ESS as a
measure of ﬂow within the stented portion of the artery and
speciﬁc stent geometries were not included into our CFD
calculations.
Study Assessments
Each 3D reconstructed artery was divided into consecutive
1.5-mm segments. Whereas 3-mm segments had been used
in the analysis of the PREDICTION study,15 we selected 1.5-
mm segments to investigate the stented regions because the
stented segments are considerably shorter than the native
coronary arteries and a ﬁner resolution for all measurements
would be required to precisely capture the local characteris-
tics of blood ﬂow and regional vascular anatomy within a
stented region. The contours of the stented region were
identiﬁed by selecting the stent struts on the IVUS image and
connecting them with a straight line, which was then
smoothed along the longitudinal course of the stented region.
Within each 1.5-mm segment, we assessed local ESS
following successful PCI at BL. The same 3D coronary artery
segments were evaluated at FU 6 to 10 months later.
Anatomic matching at BL and FU was accomplished by using
ﬁxed anatomic landmarks, multiple arterial branches, and
stent edges as reference ﬁducial points.
Within each 3D 1.5-mm stent segment, we assessed local
ESS and vessel/lumen characteristics. Each stented segment
was characterized by local predominant ESS value (deﬁned as
the minimum averaged ESS value over 90 arcs in the arterial
circumference). Vessel area, lumen area, plaque area, and ISH
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area were measured for each stented segment at both BL and
FU. Stented area was calculated as lumen area plus ISH area.
Plaque area behind the stent was calculated as vessel area
minus stent area, and the plaque burden behind the stent was
calculated as the plaque area behind the stent divided by the
vessel area. Percent ISH (%ISH) area at FU was calculated as
(ISH area/stent area 9100). Change in each parameter
(delta) was calculated as the respective FU measurement
Figure 1. Study ﬂow chart. 3D indicates three-dimensional; BL, baseline; FU, follow-up; IVUS,
intravascular ultrasound; VP, vascular proﬁling.
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minus BL measurement. Percent change in each parameter (%
delta) was calculated as (change in parameter/value of
parameter at BL 9100). Overlapping stents were deﬁned as
stents featuring an overlapping stent zone of at least 1.5 mm
in length.
In terms of clinical outcomes, we identiﬁed the BL stent
areas that were treated by subsequent PCI for ISR at FU. We
investigated the impact of BL stent characteristics on ISH and
clinical outcomes in BMS. Furthermore, we similarly examined
the anatomical outcomes in overlapping versus nonoverlap-
ping stents. Cases of in-stent thrombosis were very infrequent
and therefore not included in this analysis.
Statistical Analysis
Continuous variables are presented as the meanSD or
median and interquartile ranges (IQRs) as appropriate. To
correct for the systematic error introduced by the clustering
of stents within patients, several statistical methods were
used. First, to investigate the association of continuous
variables (eg, BL vessel area) with categorical variables (eg,
stent type), we used mixed-effects ANOVA with the patient
and stent deﬁned as random effects. Probability values were
adjusted for multiple comparisons with the use of the Scheffe
method. Second, to investigate the association of binary
outcomes (eg, subsequent PCI) with BL variables, we used
mixed-effect logistic regression with the patient and stent
deﬁned as random effect. Third, to investigate the association
of continuous outcomes (eg, ISH area) with continuous
predictors (eg, BL ESS), we used mixed effects linear
regression. BL variables associated with anatomic outcomes
on univariable analysis at P level <0.1 were considered for
entry in the respective multivariable models, and the ﬁnal
selection of independent predictors was performed with a
backward-stepping algorithm (criterion for retention, P<0.1).
In the multivariate model where outcome was the dependent
variable, baseline parameters were included as independent
variables, because all these variables were predictors of
outcome on univariable analyses with P<0.1. All statistical
tests were 2-tailed, and an a-level of 0.05 was used to
determine statistical signiﬁcance. All statistical analyses were
performed with SPSS (version 18.0; SPSS, Inc., Chicago, IL)
and Stata software (version 13.0; StataCorp LP, College
Station, TX).
The study was approved by the local institutional ethics
committee, and each patient gave written informed consent.
Table 1. Baseline Demographics
Characteristic
Available Patients
(N=186)
Female sex, n (%) 39 (21.0)
Age, y 65 (58–72)
Hypertension, n (%) 112 (60.2)
Dyslipidemia, n (%)
LDL >100 mg/dL, n (%) 139 (74.7)
HDL <40 mg/dL, n (%) 80 (43.0)
Cigarette smoking (within last 2 years), n (%) 97 (52.2)
Diabetes mellitus, n (%) 59 (31.7)
Insulin dependent, n (%) 5 (2.7)
Family history of premature CAD, n (%) 9 (4.8)
History of myocardial infarction, n (%) 9 (4.8)
History of PCI, n (%) 13 (7.0)
Continuous variable data are presented as median (interquartile range). The deﬁnition for
hypertension was blood pressure >140/90 mm Hg. CAD indicates coronary artery
disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PCI, percutaneous
coronary intervention.
Table 3. Stent Characteristics
Characteristics Total (n=246)
Subsequent
PCI (n=21)
No Subsequent
PCI (n=225)
Procedure type (%)
ACS culprit lesion 165 (67.0) 19 146
Nonculprit lesion 81 (32.9) 2 79
Vessel (%)
LAD 161 (65.4) 13 148
RCA 43 (17.5) 5 38
LCX/OM 42 (17.1) 3 39
Stent type (%)
Bare metal stent
(BMS)
100 (40.7) 12 88
Sirolimus-eluting
stent (SES)
104 (42.3) 3 101
Paclitaxel-eluting
stent (PES)
42 (17.1) 6 36
ACS indicates acute coronary syndrome; LAD, left anterior descending artery; LCX, left
circumﬂex artery; OM, obtuse marginal; PCI, percutaneous coronary intervention; RCA,
right coronary artery.
Table 2. Medication at Hospital Discharge
Medical Therapy
Available Patients
(N=186)
Statin, n (%) 131 (70.4)
Other lipid-lowering medication, n (%) 3 (1.6)
Acetylsalicylic acid, n (%) 166 (89.2)
b-blocker, n (%) 60 (32.3)
Calcium-channel blocker, n (%) 36 (19.4)
Long-acting nitrate, n (%) 26 (14.0)
ACE inhibitor/angiotensin receptor blocker, n (%) 115 (61.8)
ACE indicates angiotensin-converting enzyme.
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Results
A total of 903 stents were identiﬁed at BL in 506 patients
(Figure 1). VP at both BL and FU was performed in 374
patients (including 458 stents). Of these, regions with no
analyzable or partially analyzable stents (ie, no data for the
entire stented region) were excluded, leaving 269 fully
analyzable stented regions. Furthermore, we excluded
stents implanted before the index BL procedure and stents
with ISH at BL (n=20), Zotarolimus-eluting stents (n=2), and
stents of unknown type (n=1). In addition, segments with
incomplete stent apposition at BL (42 segments) were
excluded from this analysis. A total of 246 stents in 186
patients were ﬁnally analyzed (161 in the left anterior
descending artery, 43 in the left circumﬂex/obtuse
marginal artery, and 42 in the right coronary artery),
corresponding to a total of 3659 arterial segments (1.5-
mm-long). Fifty-four overlapping stents (833 segments)
were included in our analysis. For serial assessment of
anatomic changes and hemodynamic effects, each stented
region at BL was compared with the corresponding
segment at FU.
Patient Demographics and Stent Characteristics
Baseline characteristics of 186 patients are shown in
Table 1. A majority of patients had substantial coronary
risk factors, but only 13 (7.0%) had a history of past PCI.
There were no signiﬁcant differences of baseline character-
istics between available patients in this report and the
excluded patients. Medication at hospital discharge are
presented in Table 2. Most patients were on routine
vasculoprotective therapies. The characteristics of the 246
stents are presented in Table 3. The characteristics of the
Table 4. Baseline and Follow-Up Stent Segments Characteristics in Each Stent Type
Characteristics
Total BMS DES P Value
246 Stents, 3659
Segments
100 Stents, 1384
Segments
146 Stents, 2275
Segments BMS vs DES
VA at BL, mm2 18.485.76 20.966.17 16.974.92 <0.001
LA at BL, mm2 9.082.68 10.192.93 8.412.26 <0.001
SA at BL, mm2 9.082.68 10.192.93 8.412.26 <0.001
PA behind the stent at BL, mm2 9.393.84 10.774.00 8.553.49 <0.001
PB behind the stent at BL, % 49.639.11 50.428.56 49.159.4 <0.001
Minimum ESS at BL, Pa 1.581.00 1.420.92 1.681.03 <0.001
VA at FU, mm2 18.685.53 20.536.03 17.554.88 <0.001
LA at FU, mm2 8.082.65 7.933.05 8.162.38 <0.001
SA at FU, mm2 9.332.80 10.543.03 8.592.37 <0.001
PA behind the stent at FU, mm2 9.353.52 9.993.83 8.963.25 <0.001
PB behind the stent at FU, % 49.378.31 47.908.06 50.258.34 <0.001
ISH area at FU, mm2 1.251.72 2.621.85 0.420.94 <0.001
Delta VA, mm2 0.202.74 0.422.98 0.582.51 <0.001
Delta LA, mm2 1.011.94 2.262.04 0.251.41 <0.001
Delta SA, mm2 0.241.36 0.361.56 0.171.22 <0.001
Delta PA behind the stent, mm2 0.042.36 0.782.54 0.412.13 <0.001
Delta PB behind the stent, % 0.277.64 2.528.30 1.106.87 <0.001
%Delta VA, % 2.8516.54 0.5616.89 4.9316.00 <0.001
%Delta LA, % 9.7619.45 22.2617.99 2.1516.07 <0.001
%Delta SA, % 3.4314.37 4.4014.52 2.8314.25 <0.001
%Delta PA behind the stent, % 6.3241.70 0.3452.64 10.3632.69 <0.001
%Delta PB behind the stent, % 1.3820.40 2.6625.30 3.8416.25 <0.001
%ISH area, % 12.3915.81 25.0215.89 4.709.62 <0.001
Probability values refer to the univariate analysis and are corrected for the clustering of stents within patients. Delta is deﬁned as change in each parameter, which is calculated as
respective FU measurement minus BL measurement. BL indicates baseline; BMS, bare-metal stent; DES, drug-eluting stent; ESS, endothelia shear stress; FU, follow-up; ISH, in-stent
hyperplasia; LA, lumen area; PA, plaque area; PB, plaque burden; SA, stent area; VA, vessel area.
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3659 stent segments at BL and FU are presented in Table 4.
The mean BL ESS magnitude within the stented area after
stent deployment was 1.571.00 Pa (median, 1.34 Pa; IQR,
0.92–1.95). The frequency distribution of post-PCI BL ESS
magnitude within the stented region is shown in Figure 2,
demonstrating that ESS most commonly ranged between 1.0
and 1.5 Pa (27.8%).
Anatomical Outcomes for Each Stent Type
Among the 246 stents, including overlap stents, 100 (40.7%)
were BMS and 142 (59.3%) were DES (Table 3). Analyzing the
stented segments as consecutive 1.5-mm segments yielded
1384 segments for BMS and 2275 for DES. Anatomical
characteristics of stented segments are presented in Table 4.
The frequency distribution of ISH area by individual stent type
is shown in Figure 3. The highest proportion of ISH area at FU
was between 2.0 and 3.0 mm2 for BMS (20.1%) and between
0 and 1.0 mm2 for DES (63.0%). Because there was very little
ISH in the DES regions, we were unable to evaluate the impact
of local ESS within the stented region on ISH in these stents;
our analyses of the effect of baseline ESS within the stented
region and subsequent neointimal ISH were therefore limited
to the BMS regions.
Effect of Baseline In-Stent Characteristics on
Neointimal ISH
Large stent area and large plaque burden behind the stent
were independently associated with the magnitude of ISH
Figure 2. Distribution of post-PCI minimum ESS at BL. Distri-
bution of post-PCI minimum ESS in 1.5-mm segments at BL
(n=3659). The highest distribution range was 1.0 to 1.5 Pa
(27.8%). BL indicates baseline; ESS, endothelial shear stress; PCI,
percutaneous coronary intervention.
Figure 3. Distribution of ISH Area in BMS and DES. Distribution
of ISH area in 1.5-mm segments at FU compared with each stent
type. ISH area at FU was signiﬁcantly larger in BMS than in DES
(P<0.001). BMS indicates bare-metal stent; DES, drug-eluting stent;
FU, follow-up; ISH, in-stent hyperplasia.
Table 5. Relationship Between Baseline Stent Characteristics
and ISH Outcomes in BMS (1.5-mm Segments; n=1384):
Univariable Analyses
Outcome Baseline Predictors Beta (95% CI) P Value
ISH area,
mm2
Vessel area (per 1-mm2
increase)
0.13 (0.11–0.16) <0.001
Stent area (per 1-mm2
increase)
0.18 (0.13–0.23) <0.001
Plaque area behind the
stent (per 1-mm2
increase)
0.16 (0.13–0.19) <0.001
Plaque burden behind
the stent (per 10%
increase)
0.46 (0.34–0.58) <0.001
ESS (per 1-Pa decrease) 0.29 (0.17–0.41) <0.001
%ISH
area (%)
Vessel area (per 1-mm2
increase)
0.83 (0.63–1.02) <0.001
Stent area (per 1-mm2
increase)
0.41 (0.02–0.85) 0.064
Plaque area behind the
stent (per 1-mm2
increase)
1.22 (0.96–1.48) <0.001
Plaque burden behind
the stent (per 10%
increase)
4.94 (3.90–8.98) <0.001
ESS (per 1-Pa decrease) 1.32 (0.33–2.32 0.009
BMS indicates bare-metal stent; ESS, endothelial shear stress; ISH, in-stent hyperplasia.
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area (Tables 5 and 6). Large vessel area, large plaque burden
behind the stent, and low ESS at BL were independent
predictors of %ISH area.
Effect of ESS on Neointimal ISH in Overlapping
and Nonoverlapping Stent Segments
At BL, 9 overlapping BMS (9.0%) and 45 overlapping DES
(18.3%) were documented, corresponding to 122 and 711
segments for each stent type, respectively. There were no
signiﬁcant differences in ISH area and %ISH area between
overlapping and nonoverlapping regions in stent types. In
stented regions with overlap, low ESS at BL was not
associated with ISH outcomes in univariate analysis for BMS
(Table 7). In stented regions without overlap, low ESS at BL
was independently associated with the ISH area and %ISH
area in BMS (Table 8).
ESS and ISH in Stents Implanted at ACS Culprit
Lesions Versus Nonculprit Lesions
At BL, 165 stents (67.0%) were implanted at an ACS culprit
lesion and 81 stents (32.9%) at nonculprit lesions. In ACS
culprit lesion stents, 88 (53.3%) were BMS and 77 (46.7%)
were DES. The comparison of stented regions involving the
ACS culprit lesion and those involving the nonculprit lesion at
BL and FU is presented in Table 9. The magnitude of ESS at
BL was signiﬁcantly lower in stented segments involving the
ACS culprit lesion compared with stents at nonculprit lesions
(1.490.89 vs 1.731.15 Pa; P<0.001). Furthermore, ISH
area and %ISH area at FU were signiﬁcantly larger in stented
segments involving the ACS culprit lesion than in stents at
nonculprit lesions.
Baseline Characteristics of Stents With ISR
Requiring Subsequent PCI at FU Versus Stents
Without ISR
At FU, subsequent PCI for a signiﬁcantly worsened luminal
obstruction was performed in 21 stents (8.5%; n=242 seg-
ments). Of these, 12 stents (n=134 segments) were BMS. The
comparison of stented regions treated with or without subse-
quent PCI is shown in Table 10. The magnitude of ESS at BL
within the stented regions was not signiﬁcantly different
between the subsequent PCI group and the no subsequent PCI
group (1.541.00 vs 1.581.00 Pa; P=0.754). Figure 4
shows the distribution of ISH area at FU in the subsequent
PCI group versus the no subsequent PCI group. ISH area was
signiﬁcantly higher in the subsequent PCI group (255
1.89 mm2; median, 2.17 [IQR, 1.10–3.70]) than in the no
subsequent PCI group (1.161.67 mm2; median, 0.24 [IQR, 0–
1.85]; P<0.001).
Baseline Predictors of ISR Requiring Subsequent
PCI at FU
In univariate analyses, small stent area (per 1-mm2 decrease),
large plaque area behind the stent (per 1-mm2 increase), and
large plaque burden behind the stent (per 10% increase) were
BL predictors of subsequent PCI. In multivariable analysis,
independent predictors of subsequent PCI for ISR were small
stent area (per 1-mm2 decrease) and large plaque burden
behind the stent (per 10% increase; odds ratio [OR], 1.39; 95%
CI, 1.01–1.89; P=0.040 and OR, 2.65; 95% CI, 1.56–4.48;
P<0.001, respectively; Table 11). There was no signiﬁcant
relationship between ESS within the stented region at BL and
subsequent PCI.
Discussion
This study demonstrates, for the ﬁrst time, the effect of in-
stent ESS on subsequent ISH in a large patient population. The
main ﬁndings of this report are that: (1) ISH after BMS
implantation is independently associated with the preceding
low ESS within the stented region, regardless of whether the
stented region consists of overlapping or nonoverlapping
segments, and (2) the magnitude of ESS within the stent at BL
is not associated with ISR requiring subsequent PCI at FU.
Table 6. Independent Baseline Predictors of ISH Outcomes in
BMS (1.5-mm Segments; n=1384): Multivariable Analysis
Outcome Baseline Predictors Beta (95% CI) P Value
ISH area,
mm2
Stent area (per 1-mm2
increase)
0.21 (0.15–0.27) <0.001
Plaque burden behind
the stent (per 10%
increase)
0.59 (0.47–0.71) <0.001
ESS (per 1-Pa decrease) 0.12 (0.01–0.25) 0.072
%ISH
area (%)
Vessel area (per 1-mm2
increase)
0.27 (0.02–0.52) 0.037
Plaque burden behind
the stent (per 10%
increase)
4.50 (3.21–5.78) <0.001
ESS (per 1-Pa decrease) 1.47 (0.38–2.56) 0.008
In the multivariable model where ISH area is the dependent variable, vessel area, stent
area, plaque area behind the stent, plaque burden behind the stent, and ESS at baseline
were included as independent variables, because all these variables were predictors of
ISH area on univariable analyses with P<0.1. In this multivariable model, large stent area
and large plaque burden behind the stent were independently associated with ISH area.
In the multivariable model where % ISH area is the dependent variable, vessel area, stent
area, plaque area behind the stent, plaque burden behind the stent, and ESS at baseline
were included as independent variables. In this multivariable model, large vessel area,
large plaque burden behind the stent, and low ESS were independently associated with %
ISH area. ESS indicates endothelial shear stress; ISH, in-stent hyperplasia.
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Stent Deployment, Vascular Flow Alterations, and
ISH
The effects of arterial ﬂow alterations in stent deployment
involve multiscale phenomena. Bulk ﬂow changes attributed
to the cardiac ejection create time-dependent ﬂow and
pressure drops across vascular segments that change as a
function of vascular impedance and dimensions. Geometrical
irregularities in the vasculature, such as curvature in highly
tortuous vessel and the presence of lesions and stents, also
cause ESS variations. Physiological ESS inhibits smooth
muscle cell (SMC) proliferation and migration either directly
or through endothelial cells,21 whereas low ESS promotes the
activation, proliferation, and migration of SMCs by increasing
expression of platelet-derived growth factors, endothelin-1,
and vascular-endothelial growth factors. Therefore, native
lesions that are exposed to low ESS (ESS <1.0 Pa) exhibit
augmented plaque progression.15 Although the impact of ESS
on vascular response within a stent has been studied
before,8,11,13,18,22 data still remain inconclusive.
At the stent strut level, arterial ﬂow introduces micro-scale
near-wall ﬂow alterations, creating recirculating zones local to
the stent struts. The extent and magnitude of these ﬂow
disturbances are a function of stent dimensions, strut
conﬁguration, strut apposition relative to the arterial wall23
and stent overlap.24 These local ﬂow alterations mediate
biological responses through increased thrombogenicity25
and impaired rate of vascular repair,26 with mechanisms dif-
ferent than macro-scale effects.27 In the case of DES, the
impact of arterial drug distribution is further modulated with
variable convective transport environments.28
In this work, we show the impact of macro-scale ﬂow
alterations attributed to stent deployment on ISH in patient-
speciﬁc scenarios; we did not have appropriate data to
address micro-scale effects. Similar to an earlier study,18 our
methods included deﬁning the arterial geometry by using
IVUS and angiography and modeling the stent as a distinct
region in the arterial wall bounded by the stent struts. By
isolating the macro-scale events, we were then able to
investigate their predictive role in ISH and ISR. Local post-PCI
ESS independently predicts %ISH area in BMS, but not ISR at
FU. The absolute ISH area is dependent on stent size,
especially in BMS, and this study included various stent sizes,
as a reﬂection of its large-scale nature. However, when we
Table 7. Relationship Between Baseline Stent Characteristics of Overlapping and Nonoverlapping Stents and ISH Outcomes in
BMS: Univariable Analyses
Outcome Baseline Predictors Beta (95% CI) P Value
Overlapping stents ISH area, mm2 Vessel area (per 1-mm2 increase) 0.12 (0.097–0.14) <0.001
Stent area (per 1-mm2 increase) 0.16 (0.11–0.22) <0.001
Plaque area behind the stent (per 1-mm2 increase) 0.15 (0.11–0.18) <0.001
Plaque burden behind the stent (per 10% increase) 0.39 (0.25–0.52) <0.001
ESS (per 1-Pa decrease) 0.36 (0.22–0.50) <0.001
%ISH area (%) Vessel area (per 1-mm2 increase) 0.65 (0.44–0.85) <0.001
Stent area (per 1-mm2 increase) 0.26 (0.18 to 0.71) 0.24
Plaque area behind the stent (per 1-mm2 increase) 0.98 (0.71–1.25) <0.001
Plaque burden behind the stent (per 10% increase) 3.92 (2.79–5.06) <0.001
ESS (per 1-Pa decrease) 1.57 (0.39–2.76) 0.009
Nonoverlapping stents ISH area, mm2 Vessel area (per 1-mm2 increase) 0.12 (0.097–0.14) <0.001
Stent area (per 1-mm2 increase) 0.16 (0.11–0.22) <0.001
Plaque area behind the stent (per 1-mm2 increase) 0.15 (0.11–0.18) <0.001
Plaque burden behind the stent (per 10% increase) 0.39 (0.25–0.52) <0.001
ESS (per 1-Pa decrease) 0.36 (0.22–0.50) <0.001
%ISH area (%) Vessel area (per 1-mm2 increase) 0.65 (0.44–0.85) <0.001
Stent area (per 1-mm2 increase) 0.26 (0.18 to 0.71) 0.24
Plaque area behind the stent (per 1-mm2 increase) 0.98 (0.71–1.25) <0.001
Plaque burden behind the stent (per 10% increase) 3.92 (2.79–5.06) <0.001
ESS (per 1-Pa decrease) 1.57 (0.39–2.76) 0.009
BMS indicates bare-metal stent; ESS, endothelial shear stress; ISH, in-stent hyperplasia.
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normalized ISH area to stent area (ie, %ISH area), we identiﬁed
the relationship between ESS and local vascular responses,
which was similar to previous smaller-scale clinical stud-
ies.8,9,13 Our study showed that only 27.2% of all stents were
fully analyzable at BL and FU. The major cause of exclusion
was that VP data were not available for the entire stent
(Figure 1). However, there were no signiﬁcant differences in
baseline patient characteristics between included and
excluded stents, and a selection bias is very unlikely to
account for our results.
Impact of Eluted Compound on ISH
DES has been shown to markedly reduce the occurrence of
severe ISH.29,30 Local delivery of antineoplastic agents from
the stent strut to the arterial tissue inhibits ISH growth and
leads to clinical beneﬁt. Flow environments and arterial
patterns affect drug delivery and drug-speciﬁc
effects.28,31,32 Nevertheless, DES is not immune to ISR. In
fact, a previous study in a large cohort of patients with
angiographic surveillance reported that ISR rate remains
higher than10%.33 A recent study retrospectively analyzed
IVUS data in 298 ISR to compare the mechanisms of ISR
between BMS and DES,34 and found that both neointimal
hyperplasia (NIH) and stent under expansion were mecha-
nisms of ISR. In our study, although the lack of an ISH
response within the DES group precluded further evaluation
of the role of ﬂow in ISH outcomes in those regions, it
remains possible that NIH is large at low ESS areas within
DES.
Impact of Stent Overlap on ISH
Stent overlap occurs in more than 30% of cases, and less-
favorable outcomes are consistently reported in this setting
with both BMS4,35 and DES.14 Studies have observed more
neutrophils, eosinophils, and ﬁbrin deposition, suggestive of
more-intense inﬂammation and therefore of an underlying
ﬂow-related vascular response mechanism. In this study, we
found ESS to independently predict ISH area in nonoverlapped
segments, but, interestingly, not in the case of stent overlap.
This could either be a result of the small group size of
overlapping stents (n=54 stents) or suggest that another
scale of ﬂow could dominate in areas of stent overlap, in
particular, those micro-scale ﬂow alterations near stent struts.
When multiple stents are deployed, the inner stent will
augment further those strut-induced ﬂow alterations25 and
will increase both the area of arterial wall exposed to
prorestenotic ﬂow24 and the magnitude and amplitude of ESS
variations across the vessel. The limited resolution of our
clinical imaging did not allow for the reconstruction and
coregistration of multiscale ﬂow models and the study of
associated in vivo biological responses.
Impact of the BL Clinical Presentation on ISH
The pathophysiology and prognosis of ACS-associated
plaques is different than non-ACS-associated plaques, with
ACS plaques exhibiting a more-pronounced inﬂammatory
response than stable angina lesions. Our study showed that
the magnitude of ESS within the stented region at BL was
lower in the case of ACS, and ISH at FU was also larger.
Table 8. Independent Baseline Predictors of ISH Outcomes in Overlap Stents and Nonoverlap Stents for BMS: Multivariable
Analysis
Outcome Baseline Predictors Beta (95% CI) P Value
ISH area, mm2 Overlap stent Vessel area (per 1-mm2 increase) 0.31 (0.25–0.36) <0.001
Nonoverlap stent Vessel area (per 1-mm2 increase) 0.086 (0.054–0.12) <0.001
Plaque burden behind the stent (per 10% increase) 0.22 (0.050–0.39) 0.011
ESS (per 1-Pa decrease) 0.25 (0.088–0.41) 0.003
%ISH area (%) Overlap stent Vessel area (per 1-mm2 increase) 1.67 (0.79–2.56) <0.001
Plaque burden behind the stent (per 10% increase) 5.61 (2.34–8.88) 0.001
Nonoverlap stent Plaque burden behind the stent (per 10% increase) 4.60 (3.44–5.76) <0.001
ESS (per 1-Pa decrease) 2.69 (1.50–3.88) <0.001
In the multivariable model where ISH area with overlap stent is the dependent variable, vessel area, stent area, plaque area behind the stent, and plaque burden behind the stent at
baseline were included as independent variables, because all these variables were predictors of ISH on univariable analyses with P<0.1. In this multivariable model, large vessel area was
independently associated with ISH area with overlap. In the multivariable model where ISH area without overlap stent is the dependent variable, vessel area, stent area, plaque area behind
the stent, plaque burden behind the stent, and ESS at baseline were included as independent variables. In this multivariable model, large vessel area, plaque burden behind the stent and
low ESS were independently associated with ISH area without overlap. In the multivariable model where %ISH area with overlap stent is the dependent variable, vessel area, plaque area
behind the stent, and plaque burden behind the stent at baseline were included as independent variables, because all these variables were predictors of %ISH on univariable analyses with
P<0.1. In this multivariable model, large vessel area and large plaque behind the stent were independently associated with %ISH area with overlap. In the multivariable model where %ISH
area without overlap stent is the dependent variable, vessel area, plaque area behind the stent, plaque burden behind the stent, and ESS at baseline were included as independent
variables. In this multivariable model, plaque burden behind the stent and low ESS were independently associated with %ISH area without overlap. ESS indicates endothelial shear stress;
ISH, in-stent hyperplasia.
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Stents in ACS culprit lesions also exhibited a higher degree of
luminal narrowing from BL to FU, despite plaque regression
behind the stent. These ﬁndings might be affected by the low
ESS within the stented region at BL and the high proportion of
BMS implanted at ACS culprit lesions. Previous reports have
demonstrated that angiographic restenosis is more frequent
in patients with ACS than with stable angina, which is
consistent with our results.36
Impact of ESS on ISR Requiring Repeat PCI
Our study did not demonstrate a signiﬁcant relationship
between low ESS within the BMS stented region at BL and
occurrence of a subsequent clinically indicated PCI at FU. Low
ESSwas an independent predictor of ISH at FU, and the ISH area
Table 9. Comparison of Stent Segments at ACS Culprit
Lesion and Nonculprit Lesion
Characteristics
ACS Culprit
Lesion
(165 Stents,
2360
Segments)
Nonculprit
Lesion
(81 Stents,
1299
Segments) P Value
VA at BL, mm2 19.795.76 16.094.92 <0.001
LA at BL, mm2 9.562.75 8.212.29 <0.001
SA at BL, mm2 9.562.75 8.212.29 <0.001
PA behind the
stent at BL, mm2
10.233.82 7.883.39 <0.001
PB behind the
stent at BL, %
50.748.72 47.639.45 <0.001
Minimum ESS at
BL, Pa
1.490.89 1.731.15 0.001
VA at FU, mm2 19.735.68 16.764.69 <0.001
LA at FU, mm2 8.292.90 7.682.09 0.165
SA at FU, mm2 9.912.89 8.282.30 <0.001
PA behind the
stent at FU, mm2
9.823.61 8.493.16 <0.001
PB behind the
stent at FU, %
49.158.04 49.748.78 <0.001
ISH area at FU,
mm2
1.621.85 0.591.21 <0.001
Delta VA, mm2 0.062.94 0.682.28 <0.001
Delta LA, mm2 1.272.13 0.531.43 <0.001
Delta SA, mm2 0.341.49 0.071.06 0.459
Delta PA behind
the stent, mm2
0.402.39 0.612.18 <0.001
Delta PB behind
the stent, %
1.597.15 2.127.93 <0.001
%Delta VA, % 1.1317.04 5.9815.14 <0.001
%Delta LA, % 12.3920.63 4.9916.04 <0.001
%Delta SA, % 4.4315.15 1.5912.63 0.427
%Delta PA behind
the stent, %
1.6843.56 14.7436.63 <0.001
%Delta PB behind
the stent, %
1.4819.97 6.5920.14 <0.001
%ISH area, % 15.7316.83 6.3111.51 <0.001
Probability values refer to the univariate analysis and are corrected for the clustering of
stents within patients. ACS indicates acute coronary syndrome; BL, baseline; ESS,
endothelia shear stress; FU, follow-up; ISH, in-stent hyperplasia; LA, lumen area; PA,
plaque area; PB, plaque burden; SA, stent area; VA, vessel area.
Table 10. Comparison of Stent Segments Treated by
Subsequent PCI and No Subsequent PCI
Characteristics
Subsequent
PCI (21 Stents,
242 Segments)
No Subsequent
PCI (225 Stents,
3417 Segments) P Value
VA at BL, mm2 16.595.60 18.615.75 0.572
LA at BL, mm2 8.282.20 9.142.70 <0.001
SA at BL, mm2 8.282.20 9.142.70 <0.001
PA behind the stent
at BL, mm2
8.33.75 9.473.84 0.006
PB behind the stent
at BL, %
48.427.76 49.729.19 <0.001
Minimum ESS at BL, Pa 1.541.00 1.581.00 0.754
VA at FU, mm2 17.145.36 18.795.53 0.537
LA at FU, mm2 5.981.89 8.222.64 <0.001
SA at FU, mm2 8.532.45 9.382.82 0.001
PA behind the stent at
FU, mm2
8.613.61 9.403.51 0.280
PB behind the stent at
FU, %
49.308.41 49.378.31 0.002
ISH area at FU, mm2 2.551.89 1.161.67 <0.001
Delta VA, mm2 0.552.62 0.182.75 0.145
Delta LA, mm2 2.301.85 0.921.92 <0.001
Delta SA, mm2 0.241.12 0.241.37 0.671
Delta PA behind the
stent, mm2
0.312.60 0.072.34 0.036
Delta PB behind the
stent, %
0.889.29 0.357.51 0.187
%Delta VA, % 6.0719.93 2.6316.27 0.280
%Delta LA, % 26.2918.62 8.5818.97 <0.001
%Delta SA, % 3.1313.04 3.4414.46 0.899
%Delta PA behind the
stent, %
14.0255.47 5.7740.50 0.174
%Delta PB behind the
stent, %
3.9123.93 1.2020.12 0.192
%ISH area, % 28.1816.68 11.2515.14 <0.001
Probability values refer to the univariate analysis and are corrected for the clustering of
stents within patients. BL indicates baseline; ESS, endothelia shear stress; FU, follow-up;
ISH, in-stent hyperplasia; LA, lumen area; PA, plaque area; PB, plaque burden; PCI,
percutaneous coronary intervention; SA, stent area; VA, vessel area.
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at FU was signiﬁcantly larger in stents with FU ISR PCI than in
those without ISR. Given that late lumen loss correlates with
neointimal tissue proliferation, the magnitude of ISH concep-
tually contributes to a clinically dictated revascularization. Our
results indicate, however, that though low ESS was associated
with ISH during this short-term FU, there was not sufﬁcient ISH
that would cause ISR and warrant repeat revascularization.
Study Limitations
Our study had several limitations. We did not collect information
concerning the speciﬁc type of BMS utilized. Although stent
design and conﬁguration are important for the hemodynamic
environment, our deﬁnition of ﬂow in this study was a
macroscopic measure of ﬂow in the stented region and did
not reﬂect the microscopic ﬂow patterns associated with
speciﬁc stent geometries. We were also limited to BMS cases
only in ISH assessment because there was very little ISH
observed in DES. Our study is also limited by the small number
of clinical events that occurred within the short FU period.Many
of these clinical events were asymptomatic, consisting of
signiﬁcant in-stent lumen narrowing identiﬁed during routine FU
cardiac catheterization and, accordingly, treated with a PCI.
Although in-stent thrombosis occurred in a few cases, it was not
feasible to obtain VP data in those emergency clinical
situations. Therefore, we were not able to investigate the
relationship between ESS within the stent and late or very late
stent thrombosis, which is an important component in the
management of patients with DES.
Conclusions
ISH after stent implantation relates to preceding low ESS
within the stent. ISH is strongly inhibited by DES. ESS is not
associated with ISR requiring subsequent PCI at FU. Although
low ESS is independently associated with ISH, it does not
predict ISH of sufﬁciently large magnitude to cause clinically
evident lumen obstruction. ESS is an important determinant
of ISH after stent implantation, but pronounced ISH during
this short FU is likely attributed to factors other than local
ESS within the stented region.
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Figure 4. Distribution of ISH area with subsequent PCI or not.
Distribution of ISH area in 1.5-mm segments at FU compared with
subsequent PCI group and no subsequent PCI group. There were
242 segments (BMS, 134 segments [55.3%]; DES, 108 segments
[44.6%]) in subsequent PCI group and 3417 segments (BMS, 1250
segments [36.6%]; DES, 2167 segments [63.4%]) in no subsequent
PCI group. ISH area at FU was signiﬁcantly larger in subsequent PCI
group than in no subsequent PCI group (P<0.001). BMS indicates
bare-metal stent; DES, drug-eluting stent; FU, follow-up; ISH, in-
stent hyperplasia; PCI, percutaneous coronary intervention.
Table 11. Baseline Anatomic Predictors of Subsequent PCI
Baseline Predictor
Odds Ratio
(95% CI) P Value
Univariable
analysis
Vessel wall area (per 1-
mm2 increase)
1.04 (0.94–1.16) 0.448
Stent area (per 1-mm2
decrease)
1.56 (1.15–2.11) 0.004
Plaque area behind the
stent (per 1-mm2
increase)
1.30 (1.11–1.53) 0.001
Plaque burden behind
the stent (per 10%
increase)
3.00 (1.78–5.07) <0.001
ESS (per 1-Pa
decrease)
0.79 (0.45–1.39) 0.416
Multivariable
analysis
Stent area (per 1-mm2
decrease)
1.39 (1.01–1.89) 0.040
Plaque burden behind
the stent (per 10%
increase)
2.65 (1.56–4.48) <0.001
In the multivariable model where subsequent PCI is the dependent variable, stent area,
plaque area behind the stent, and plaque burden behind the stent at baseline were
included as independent variables, because all these variables were predictors of
subsequent PCI on univariable analyses with P<0.1. In this multivariable model, small
stent area and large plaque burden behind the stent were independently associated with
subsequent PCI. ESS indicates endothelial shear stress; PCI, percutaneous coronary
intervention.
DOI: 10.1161/JAHA.115.002949 Journal of the American Heart Association 11
Endothelial Shear Stress & In-Stent Hyperplasia Shishido et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
Disclosures
None.
References
1. Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, Kent
KM, Grifﬁn J, Leon MB. Patterns and mechanisms of in-stent restenosis. A
serial intravascular ultrasound study. Circulation. 1996;94:1247–1254.
2. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C,
Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE;
Investigators S. Sirolimus-eluting stents versus standard stents in patients
with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323.
3. Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, Sousa
E, Stoll HP; Investigators RT. Sirolimus- vs paclitaxel-eluting stents in de novo
coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA.
2006;295:895–904.
4. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent
restenosis: contributions of inﬂammatory responses and arterial injury to
neointimal hyperplasia. J Am Coll Cardiol. 1998;31:224–230.
5. van Beusekom HM, Whelan DM, Hofma SH, Krabbendam SC, van Hinsbergh
VW, Verdouw PD, van der Giessen WJ. Long-term endothelial dysfunction is
more pronounced after stenting than after balloon angioplasty in porcine
coronary arteries. J Am Coll Cardiol. 1998;32:1109–1117.
6. Koskinas KC, Chatzizisis YS, Antoniadis AP, Giannoglou GD. Role of endothelial
shear stress in stent restenosis and thrombosis: pathophysiologic mecha-
nisms and implications for clinical translation. J Am Coll Cardiol.
2012;59:1337–1349.
7. Wentzel JJ, Gijsen FJ, Schuurbiers JC, van der Steen AF, Serruys PW. The
inﬂuence of shear stress on in-stent restenosis and thrombosis. EuroInter-
vention. 2008;4 suppl C:C27–C32.
8. Wentzel JJ, Krams R, Schuurbiers JCH, Oomen JA, Kloet J, van der Giessen WJ,
Serruys PW, Slager CJ. Relationship between neointimal thickness and shear
stress after Wallstent implantation in human coronary arteries. Circulation.
2001;103:1740–1745.
9. Sanmartin M, Goicolea J, Garcia C, Garcia J, Crespo A, Rodriguez J, Goicolea
JM. Inﬂuence of shear stress on in-stent restenosis: in vivo study using 3D
reconstruction and computational ﬂuid dynamics. Rev Esp Cardiol.
2006;59:20–27.
10. Papafaklis MI, Bourantas CV, Theodorakis PE, Katsouras CS, Fotiadis DI,
Michalis LK. Relationship of shear stress with in-stent restenosis: bare metal
stenting and the effect of brachytherapy. Int J Cardiol. 2009;134:25–32.
11. Gijsen FJ, Oortman RM, Wentzel JJ, Schuurbiers JC, Tanabe K, Degertekin M,
Ligthart JM, Thury A, de Feyter PJ, Serruys PW, Slager CJ. Usefulness of shear
stress pattern in predicting neointima distribution in sirolimus-eluting stents in
coronary arteries. Am J Cardiol. 2003;92:1325–1328.
12. Suzuki N, Nanda H, Angiolillo DJ, Bezerra H, Sabate M, Jimenez-Quevedo P,
Alfonso F, Macaya C, Bass TA, Ilegbusi OJ, Costa MA. Assessment of potential
relationship between wall shear stress and arterial wall response after bare
metal stent and sirolimus-eluting stent implantation in patients with diabetes
mellitus. Int J Cardiovasc Imaging. 2008;24:357–364.
13. Papafaklis MI, Bourantas CV, Theodorakis PE, Katsouras CS, Naka KK, Fotiadis
DI, Michalis LK. The effect of shear stress on neointimal response following
sirolimus- and paclitaxel-eluting stent implantation compared with bare-metal
stents in humans. JACC Cardiovasc Interv. 2010;3:1181–1189.
14. Raber L, Juni P, Loffel L, Wandel S, Cook S, Wenaweser P, Togni M, Vogel R,
Seiler C, Eberli F, Luscher T, Meier B, Windecker S. Impact of stent overlap on
angiographic and long-term clinical outcome in patients undergoing drug-
eluting stent implantation. J Am Coll Cardiol. 2010;55:1178–1188.
15. Stone PH, Saito S, Takahashi S, Makita Y, Nakamura S, Kawasaki T, Takahashi
A, Katsuki T, Nakamura S, Namiki A, Hirohata A, Matsumura T, Yamazaki S,
Yokoi H, Tanaka S, Otsuji S, Yoshimachi F, Honye J, Harwood D, Reitman M,
Coskun AU, Papafaklis MI, Feldman CL; Investigators P. Prediction of
progression of coronary artery disease and clinical outcomes using vascular
proﬁling of endothelial shear stress and arterial plaque characteristics: the
PREDICTION Study. Circulation. 2012;126:172–181.
16. Feldman CL, Ilegbusi OJ, Hu Z, Nesto R, Waxman S, Stone PH. Determination
of in vivo velocity and endothelial shear stress patterns with phasic ﬂow in
human coronary arteries: a methodology to predict progression of coronary
atherosclerosis. Am Heart J. 2002;143:931–939.
17. Coskun AU, Yeghiazarians Y, Kinlay S, Clark ME, Ilegbusi OJ, Wahle A, Sonka
M, Popma JJ, Kuntz RE, Feldman CL, Stone PH. Reproducibility of coronary
lumen, plaque, and vessel wall reconstruction and of endothelial shear stress
measurements in vivo in humans. Catheter Cardiovasc Interv. 2003;60:67–78.
18. Stone PH, Coskun AU, Kinlay S, Clark ME, Sonka M, Wahle A, Ilegbusi OJ,
Yeghiazarians Y, Popma JJ, Orav J, Kuntz RE, Feldman CL. Effect of endothelial
shear stress on the progression of coronary artery disease, vascular
remodeling, and in-stent restenosis in humans: in vivo 6-month follow-up
study. Circulation. 2003;108:438–444.
19. Chatzizisis YS, Jonas M, Coskun AU, Beigel R, Stone BV, Maynard C, Gerrity
RG, Daley W, Rogers C, Edelman ER, Feldman CL, Stone PH. Prediction of the
localization of high-risk coronary atherosclerotic plaques on the basis of low
endothelial shear stress: an intravascular ultrasound and histopathology
natural history study. Circulation. 2008;117:993–1002.
20. Sakamoto S, Takahashi S, Coskun AU, Papafaklis MI, Takahashi A, Saito S,
Stone PH, Feldman CL. Relation of distribution of coronary blood ﬂow volume
to coronary artery dominance. Am J Cardiol. 2013;111:1420–1424.
21. Ueba H, Kawakami M, Yaginuma T. Shear stress as an inhibitor of vascular
smooth muscle cell proliferation. Role of transforming growth factor-beta 1
and tissue-type plasminogen activator. Arterioscler Thromb Vasc Biol.
1997;17:1512–1516.
22. Bourantas CV, Papafaklis MI, Kotsia A, Farooq V, Muramatsu T, Gomez-Lara J,
Zhang YJ, Iqbal J, Kalatzis FG, Naka KK, Fotiadis DI, Dorange C, Wang J, Rapoza
R, Garcia-Garcia HM, Onuma Y, Michalis LK, Serruys PW. Effect of the
endothelial shear stress patterns on neointimal proliferation following drug-
eluting bioresorbable vascular scaffold implantation: an optical coherence
tomography study. JACC Cardiovasc Interv. 2014;7:315–324.
23. O’Brien CC, Finch CH, Barber TJ, Martens P, Simmons A. Analysis of drug
distribution from a simulated drug-eluting stent strut using an in vitro
framework. Ann Biomed Eng. 2012;40:2687–2696.
24. Rikhtegar F, Wyss C, Stok KS, Poulikakos D, Muller R, Kurtcuoglu V.
Hemodynamics in coronary arteries with overlapping stents. J Biomech.
2014;47:505–511.
25. Kolandaivelu K, Swaminathan R, Gibson WJ, Kolachalama VB, Nguyen-
Ehrenreich KL, Giddings VL, Coleman L, Wong GK, Edelman ER. Stent
thrombogenicity early in high-risk interventional settings is driven by stent
design and deployment and protected by polymer-drug coatings. Circulation.
2011;123:1400–1409.
26. Foin N, Gutierrez-Chico JL, Nakatani S, Torii R, Bourantas CV, Sen S, Nijjer S,
Petraco R, Kousera C, Ghione M, Onuma Y, Garcia-Garcia HM, Francis DP,
Wong P, Di Mario C, Davies JE, Serruys PW. Incomplete stent apposition
causes high shear ﬂow disturbances and delay in neointimal coverage as a
function of strut to wall detachment distance: implications for the
management of incomplete stent apposition. Circ Cardiovasc Interv.
2014;7:180–189.
27. Jimenez JM, Prasad V, Yu MD, Kampmeyer CP, Kaakour AH, Wang PJ, Maloney
SF, Wright N, Johnston I, Jiang YZ, Davies PF. Macro- and microscale variables
regulate stent haemodynamics, ﬁbrin deposition and thrombomodulin expres-
sion. J R Soc Interface. 2014;11:20131079.
28. Balakrishnan B, Tzafriri AR, Seifert P, Groothuis A, Rogers C, Edelman ER. Strut
position, blood ﬂow, and drug deposition: implications for single and
overlapping drug-eluting stents. Circulation. 2005;111:2958–2965.
29. Stefanini GG, Holmes DR Jr. Drug-eluting coronary-artery stents. N Engl J Med.
2013;368:254–265.
30. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting
stents: Part I. Circulation. 2003;107:2274–2279.
31. O’Brien CC, Kolachalama VB, Barber TJ, Simmons A, Edelman ER. Impact of
ﬂow pulsatility on arterial drug distribution in stent-based therapy. J Control
Release. 2013;168:115–124.
32. Tzafriri AR, Vukmirovic N, Kolachalama VB, Astaﬁeva I, Edelman ER. Lesion
complexity determines arterial drug distribution after local drug delivery. J
Control Release. 2010;142:332–338.
33. Cassese S, Byrne RA, Tada T, Pinieck S, Joner M, Ibrahim T, King LA, Fusaro M,
Laugwitz KL, Kastrati A. Incidence and predictors of restenosis after coronary
stenting in 10004 patients with surveillance angiography. Heart.
2014;100:153–159.
34. Goto K, Zhao Z, Matsumura M, Dohi T, Kobayashi N, Kirtane AJ, Rabbani LE,
Collins MB, Parikh MA, Kodali SK, Leon MB, Moses JW, Mintz GS, Maehara A.
Mechanisms and patterns of intravascular ultrasound in-stent restenosis
among bare metal stents and ﬁrst- and second-generation drug-eluting stents.
Am J Cardiol. 2015;116:1351–1357.
35. Ellis SG, Savage M, Fischman D, Baim DS, Leon M, Goldberg S, Hirshfeld JW,
Cleman MW, Teirstein PS, Walker C. Restenosis after placement of Palmaz-
Schatz stents in native coronary arteries. Initial results of a multicenter
experience. Circulation. 1992;86:1836–1844.
36. Assali AR, Moustapha A, Sdringola S, Denktas AE, Willerson JT, Holmes DR Jr,
Smalling RW. Acute coronary syndrome may occur with in-stent restenosis
and is associated with adverse outcomes (the PRESTO trial). Am J Cardiol.
2006;98:729–733.
DOI: 10.1161/JAHA.115.002949 Journal of the American Heart Association 12
Endothelial Shear Stress & In-Stent Hyperplasia Shishido et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
